|
|
Vaccine Detail
|
Renal Cell Carcinoma Peptides Vaccine IMA901 |
| Vaccine Information |
- Vaccine Name: Renal Cell Carcinoma Peptides Vaccine IMA901
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007172
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- HLA-B
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- HLA-A
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: IMA901 for clinical phase 1 was formulated by mixing solutions of the 11 peptides lyophilised without the addition of excipients and resolubized with 4.2% sodium bicarbonate buffer. For clinical phase 2, the formulation of IMA901 comprised all peptides also used for phase 1, with the exception of HBV-001, with added mannitol and poloxamer 188 as excipients (Walter et al., 2012).
- Description: This is for Renal Cancer (NCT00523159). A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens (Bedke and Stenzl, 2013; NCIT_C70968).
|
| Host Response |
|
|
| References |
Bedke and Stenzl, 2013: Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma. Expert opinion on investigational drugs. 2013; 22(10); 1329-1336. [PubMed: 23899354].
NCIT_C70968: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70968]
NCT00523159: [https://clinicaltrials.gov/show/NCT00523159/]
Walter et al., 2012: Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature medicine. 2012; 18(8); 1254-1261. [PubMed: 22842478].
|
|
